Transfusion independence in patients with myelodysplastic syndromes: Impact on outcomes and quality of life

Cancer

Volumn 106, Issue 10, 2006, Pages 2087-2094

  Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Anemia; Myelodysplastic syndromes; Quality of life; Transfusion; Treatment

Indexed keywords

CYCLOSPORIN; DEFEROXAMINE; DIFFERENTIATION INDUCING FACTOR; ERYTHROPOIETIC GROWTH FACTOR; GROWTH FACTOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IRON CHELATING AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALPROIC ACID;

5Q- SYNDROME; ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; META ANALYSIS; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SURVIVAL; TRANSFUSION INDEPENDENCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646363066     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21860     Document Type: Review

References (49)

1. Hofmann W-K, Lubbert M, Hoelzer D, Koeffler HP. Myelodysplastic syndromes. Hematol J. 2004;5:1-8.
2. Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes. Int J Hematol. 1999;70:141-154.
3. Lawrence LW. Refractory anemia and the myelodysplastic syndromes. Clin Lab Sci. 2004;17:178-186.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood. 1998;91:1100]. Blood. 1997;89:2079-2088.
5. National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members. NCCN practice guidelines: myelodysplastic syndromes, version 1, 2005. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf [accessed August 12, 2005].
6. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
7. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070-1074.
8. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al, for the Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037-1046.
9. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536-538.
10. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953-959.
11. Bowen D, Culligan D, Jowitt S, et al, of the UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187-200.
12. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910-935.
13. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep. 2003;2:122-129.
14. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines on the clinical use of leucocyte-depleted blood components. Transfus Med. 1998;8:59-71.
15. Brechignac S, Hellstrom-Lindberg E, Bowen DT, DeWitt TM, Cazzola M, Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS) [abstract 4716]. Blood. 2004;104(Part 2):263b.
16. Fitzgerald M, Hodgkinson B, Thorp D. Blood transfusion from the recipient's perspective. J Clin Nurs. 1999;8:593-600.
17. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med. 1991;90:338-344.
18. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
19. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol. 2005;18:289-298.
20. Kleinman S, Marshall D, AuBuchon J, Patton M. Survival after transfusion as assessed in a large multistate US cohort. Transfusion. 2004;44:386-390.
21. Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion. 2004;44:1025-1032.
22. Amin M, Fergusson D, Aziz A, Wilson K, Coyle D, Hebert P. The cost of allogeneic red blood cells-a systematic review. Transfus Med. 2003;13:275-285.
23. Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion. 2004;44:1479-1486.
24. Casadevall N, Durieux P, Dubois S, et al, for The Groupe Francais des Myelodyplasies. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:321-327.
25. Jansen AJG, Essink-Bot M-L, Beckers EAM, Hop WCJ, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270-274.
26. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, for the Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39:335-345.
27. Clavio M, Nobili F, Balleari E, et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol. 2004;72:113-120.
28. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995;89:67-71.
29. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076-4081.
30. Mannone L, Gardin C, Quarre MC, Bernard JF, Giraudier S, Rosenthal E. High response rate to darbopoietin alfa in "low risk" MDS: results of Phase II study [abstract 69]. Blood. 2004;104(Part 1):24a.
31. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol. 2005;128:204-209.
32. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137:156-163.
33. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120:679-684.
34. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res. 2003;27:783-788.
35. Raza A, Candoni A, Khan U, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma. 2004;45:2099-2104.
36. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102:3025-3027.
37. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.
38. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
39. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005;104:101-109.
40. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
41. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1-6.
42. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004;28:325-332.
43. Moreno-Aspitia A, Geyer S, Li C-Y, et al. N998B: multicenter Phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS) [abstract 354]. Blood. 2002;100:96a.
44. Bouscary D, Quarre MC, Vassilief D, et al. Thalidomide for the treatment of low risk myelodysplasia. The Thal-SMD-200 Trial from the French Group of Myelodysplasia (GFM) [abstract 1438]. Blood. 2004;104(Suppl):403a.
45. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
46. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
47. List AF, Dewald G, Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 Study [abstract 5]. J Clin Oncol. 2005;23:2s.
48. List AF, Gewald G, Bennett J, et al. Results of the MDS-002 and -003 international Phase II studies evaluating lenalidomide (CC-5013; Revlimida) in the treatment of transfusion-dependent (TD) patients with myelodysplastic syndrome (MDS) [abstract 0772]. Haematologica. 2005;90(Suppl 2):307-308.
49. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. Br J Cancer. 2005;93:613-619.